A phase 2 trial of verubulin for recurrent glioblastoma: A prospective study by the brain tumor investigational consortium (BTIC)

Journal of Neuro-Oncology

Volumn 118, Issue 2, 2014, Pages 335-343

  Chamberlain, Marc C ^a   Grimm, Sean ^b   Phuphanich, Surasak ^c   Recht, Larry ^d   Zhu, Jay Z ^e   Kim, Lyndon ^f   Rosenfeld, Steve ^g   Fadul, Camilo E ^h  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

^e TUFTS UNIVERSITY   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Bevacizumab na ve refractory; Recurrent glioblastoma; Vascular disrupting agent; Verubulin (Azixa)

Indexed keywords

BEVACIZUMAB; DRUG METABOLITE; MPI 0440627; UNCLASSIFIED DRUG; VERUBULIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BRAIN ISCHEMIA; BRAIN TUMOR; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HEART INFARCTION; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; AGED; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; QUINAZOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903900522     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1437-y     Document Type: Article

References (35)

1. Ostrom QT, Gittleman H, Farah P, Onderacek A, Chen Y, Wolinsjy Y, Stroup NE, Kruchko C, Branholtz-Sloan J (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15:ii1-ii56
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987-996
3. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492-507
4. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J (2010) Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16:2443-2449
5. Chamberlain M (2011) Evolving strategies: future treatment of glioblastoma. Expert Rev Neurother 11:519-532
6. Grimm S, Chamberlain MC (2012) State of art and perspectives on the treatment of glioblastoma. CNS Oncol 1:49-70
7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
8. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745
9. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787
10. Kargiotis O, Rao J, Kyritsis AP et al (2006) Mechanisms of angiogenesis in gliomas. J Neuro Oncol 78:281-293
11. Minchinton A, Tannock I (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583-592
12. Tozer GM, Kanthou C, Baguley BC et al (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5(6):423-435
13. Siemann D, Bibby M, Dark GG, Dicker AP, Eskens FA, Horsman MR et al (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11(2 pt 1):416-420
14. Lippert J 3rd (2007) Vascular disrupting agents. Bioorg Med Chem 15:605-615
15. Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S et al (2007) MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Can Res 67:5865-5871
16. Sirisoma N, Pervin A, Zhang H, Jiang S, Adam Willardsen J, Anderson MB et al (2010) Discovery of N-methyl-4-(4-methoxyanilino) quinazolines as potent apoptosis inducers. Structure-activity relationship of the quinazoline ring. Bioorg Med Chem Lett 20:2330-2334
17. Sirisoma N, Pervin A, Zhang H, Jiang S, Willardsen JA, Anderson MB et al (2009) Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration. J Med Chem 52:2341-2351
18. Pleiman C, Baichwal V, Bhoite L, et al (2007) Vascular disruption effects of MPC-6827. In: 98th Annual Meeting of the American Association for Cancer Research (AACR), 2007 in Los Angeles, California (Abstract/Poster)
19. Jessing K, Mauck K, Bradford C, et al (2005) MPC-6827, a small molecule inhibitor of microtubule formation with high brain penetration: absorption, distribution, metabolism, excretion, and clinical considerations. In: 96th Annual Meeting of the American Association for Cancer Research (AACR), 2005 in Anaheim, California (Abstract/Poster)
20. Yu MK (2009) MPC-6827: Anti-tumor activity in an orthotopic brain model and in combination with bevacizumab. In: The 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the AANS/CNS Section, October 23, 2009 in New Orleans, LA
21. Jones JT (2009) MPC-6827: A potent tubulin binding and vascular disrupting agent with high brain penetration and anti-tumor activity in a mouse orthotopic glioma model. In: The 100th meeting of the American Association for Cancer Research (AACR), April 22, 2009 in Denver, CO
22. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
23. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170
24. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9:29-38
25. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D et al (2007) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11:550-555
26. Chamberlain MC, Johnston SK (2010) Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neuro-Oncol 96:259-269
27. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C et al (2010) Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther 9:3410-3419
28. Hwu WJ, Akerley WL, Stephenson J, et al (2010) Final report: MPC-6827 is safely combined with temozolomide for the treatment of patients with metastatic melanoma. J Clin Oncol 28: 15 s (Suppl; abstr 8531)
29. Grossman K, Colman H, Akerley W, Glantz M, Matsuoko Y, Beelen AP et al (2012) Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. Neuro Oncol 110:257-264
30. Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
31. Wen P, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol 28:1963-1972
32. van Heeckeren WJ, Bhakta S, Ortiz J, Duerk J, Cooney MM, Dowlati A et al (2006) Promise of new vascular-disrupting agents balanced with cardiac toxicity: Is it time for oncologists to get to know their cardiologists? J Clin Oncol 24:1485-1488
33. LoRusso PM, Boerner SA, Hunsberger S (2011) Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? J Clin Oncol 29:2952-2955
34. Wang ES, Pili R, Seshadri M (2012) Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule. J Clin Oncol 30:760-761
35. Bottsford-Miller JN, Colleman RL, Sood AK (2012) Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 30:4026-4034